Lipocalin fusion partners

Abstract

Methods and systems for producing fusion proteins and peptides are disclosed. Fusion proteins and peptides created using the methods are also provided. Also provided are methods of using the fusion proteins and peptides produced according to the present disclosure.

What is claimed is: 
     
         1 . A method for producing a fusion protein, the method comprising expressing, in a cell, a fusion protein, the fusion protein comprising human siderocalin and trastuzumab or a fragment thereof. 
     
     
         2 . A method of  claim 1 , wherein the expressing utilizes the parental cloning construct of SEQ ID NO: 37. 
     
     
         3 . A method of  claim 1 , wherein the fusion protein comprises trastuzumab. 
     
     
         4 . A method of  claim 1 , wherein the fusion protein comprises a fragment of trastuzumab. 
     
     
         5 . A method of  claim 4 , wherein the fragment is a Fab fragment. 
     
     
         6 . A method of  claim 1 , further comprising associating the human siderocalin with a radionuclide. 
     
     
         7 . A method of  claim 5 , wherein the radionuclide is selected from Sc-47, Ga-67, Y-90, Ag-111, In-111, Sm-153, Tb-166, Lu-177, Bi-213, Ac-225, Cu-64, Cu-67, Pd-109, Ag-111, Re-186, Re-188, Pt-197, Bi-212, Bi-213, Pb-212 or Ra-223. 
     
     
         8 . A fusion protein produced by the method of  claim 1 . 
     
     
         9 . A fusion protein of  claim 7 , wherein the fusion protein comprises trastuzumab. 
     
     
         10 . A fusion protein of  claim 7 , wherein the fusion protein comprises a fragment of trastuzumab. 
     
     
         11 . A fusion protein of  claim 10 , wherein the fragment is a Fab fragment. 
     
     
         12 . A fusion protein of  claim 7 , wherein the human siderocalin is associated with a radionuclide. 
     
     
         13 . A fusion protein of  claim 12 , wherein the radionuclide is selected from Sc-47, Ga-67, Y-90, Ag-111, In-111, Sm-153, Tb-166, Lu-177, Bi-213, Ac-225, Cu-64, Cu-67, Pd-109, Ag-111, Re-186, Re-188, Pt-197, Bi-212, Bi-213, Pb-212 or Ra-223. 
     
     
         14 . A method for producing a fusion protein, the method comprising expressing, in a cell, a fusion protein, the fusion protein comprising human siderocalin and infliximab or a fragment thereof, adalimumab or a fragment thereof, OKT3 or a fragment thereof, or Fc. 
     
     
         15 . A method of  claim 14 , wherein the expressing utilizes the parental cloning construct of SEQ ID NO: 37. 
     
     
         16 . A method of  claim 14 , wherein the fusion protein comprises infliximab, adalimumab, OKT3, or Fc. 
     
     
         17 . A method of  claim 14 , wherein the fusion protein comprises a fragment of infliximab, a fragment of adalimumab, or a fragment of OKT3. 
     
     
         18 . A method of  claim 17 , wherein the fragment is a Fab fragment. 
     
     
         19 . A method of  claim 14 , further comprising associating the human siderocalin with a radionuclide. 
     
     
         20 . A method of  claim 19 , wherein the radionuclide is selected from Sc-47, Ga-67, Y-90, Ag-111, In-111, Sm-153, Tb-166, Lu-177, Bi-213, Ac-225, Cu-64, Cu-67, Pd-109, Ag-111, Re-186, Re-188, Pt-197, Bi-212, Bi-213, Pb-212 or Ra-223.